Vol 21 No 3 (2015)
Journal of Commercial Biotechnology
Journal of Commercial Biotechnology
Subscribe
Current
Archives
Search
About
About the Journal
Submissions
Editorial Team
Privacy Statement
Contact
Register
Login
Register
Login
Vol 21 No 3 (2015)
Published July 1, 2015
Commentary
Menghis Bairu
Combating a Global Pandemic of Weak, Adulterated, and Fake Drugs
Requires Subscription or Fee
PDF
Peter J. Pitts
The Globetrotting Regulator
Requires Subscription or Fee
PDF
Peter Pitts
FDA: Is Off-Label on the Table?
Requires Subscription or Fee
PDF
Henry I Miller, Graham Brookes
A ‘Genetically Engineered’ Label: Way More Expensive Than You Think
Requires Subscription or Fee
PDF
Articles
Clifford S Mintz, Evan Nison, AJ Fabrizio
Cannabis-Derived Pharmaceuticals
Requires Subscription or Fee
PDF
Kenneth Fernald, Ruud Hoeben, Eric Claassen
Venture Capitalists as gatekeepers for Biotechnological Innovation
Requires Subscription or Fee
PDF
From the Boardroom
Ian C. Clift
BioTime’s bid to end age-related disease: A look at CEO Michael West’s Vision
Requires Subscription or Fee
PDF
Legal and Regulatory Updates
Henry Elliott
EU Legal & Regulatory Update – May 2015
Requires Subscription or Fee
PDF
Conference Report
Vasu Pestonjamasp
Innovation Landscape, Deal-making Strategies and Success Stories
Requires Subscription or Fee
PDF
×
Username
*
Required
Password
*
Required
Forgot your password?
Keep me logged in
Login
No account?
Register here